Literature DB >> 1000058

Determined of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection.

R J Francis, P B East, S J McLaren, J Larman.   

Abstract

A sensitive method for the simulataneous determination of bufuralol and its pharmacologically active metabolites in huamn plasma is described. The O-timethylsilyl,N-trifluoroacetyl derivatives are assayed by mass fragmentography. Sensitivity is 1 ng 76(-1) plasma for bufaralol and about 250 pg ml(-1) for the metabolites. An alternative procedure which uses gas chromatography with electron capture detection is also described. The sensitivity of this is about 10 ng ml(-1) plasma for all drug-related components.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1000058     DOI： 10.1002/bms.1200030606

Source DB:  PubMed          Journal:  Biomed Mass Spectrom        ISSN： 0306-042X


  10 in total

Review 1.  Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.

Authors:  Nicholas Bodor; Peter Buchwald
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695

2.  Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β-Blockers1?2.

Authors:  N Bodor; Y Oshiro; T Loftsson; M Katovich; W Caldwell
Journal:  Pharm Res       Date:  1984-05       Impact factor: 4.200

3.  Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.

Authors:  P Dayer; A Kubli; A Kupfer; F Courvoisier; L Balant; J Fabre
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 4.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 5.  Oxidation phenotype and the metabolism and action of beta-blockers.

Authors:  M S Lennard
Journal:  Klin Wochenschr       Date:  1985-04-01

6.  The genetic control of bufuralol metabolism in man.

Authors:  P Dayer; L Balant; F Courvoisier; A Kupfer; A Kubli; A Gorgia; J Fabre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

7.  Influence of renal failure on the hepatic clearance of bufuralol in man.

Authors:  L Balant; R J Francis; T N Tozer; A Marmy; J M Tschopp; J Fabre
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

8.  Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol.

Authors:  R J Francis; P B East; J Larman
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Pharmacodynamic and pharmacokinetic studies on bufuralol in man.

Authors:  T H Pringle; R J Francis; P B East; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

10.  Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.

Authors:  P Dayer; T Leemann; A Küpfer; T Kronbach; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.